Status:
Concluded with an LOI
Manufacturer:
Accord Healthcare Inc.
Indication:
For the treatment of adult patients with advanced prostate cancer
Last updated October 31, 2025
Status:
Concluded without agreement
Manufacturer:
Nordic Pharma
Indication:
Multiple Indications
Last updated October 30, 2025
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Multiple Indications
Last updated October 29, 2025
Abilify Asimtufii (aripiprazole)
Status:
Concluded with an LOI
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Schizophrenia
Last updated October 24, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ? 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.
Last updated October 23, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
Last updated October 23, 2025
Ferinject (ferric carboxymaltose)
Status:
Concluded with an LOI
Manufacturer:
CSL Vifor
Indication:
Iron Deficiency Anemia
Last updated October 17, 2025
Ferinject (ferric carboxymaltose)
Status:
Concluded with an LOI
Manufacturer:
CSL Vifor
Indication:
Iron deficiency in adult patients with heart failure
Last updated October 17, 2025
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Advanced Systemic Mastocytosis
Last updated October 17, 2025
Status:
Concluded with an LOI
Manufacturer:
Mantra Pharma
Indication:
Multiple Indications
Last updated October 14, 2025